Page 4 - Sciences Group News Today

Julie Dotton, 51, of Orchard Park, president and CEO of Applied Sciences Group and founding partner of KRP Holdings, who did not pay more than $1.1 million in employment taxes,

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response in r/r Peripheral T-cell Lymphomas ; ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient...

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) and Imunon (NASDAQ:IMNN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Risk and Volatility SELLAS Life Sciences […]

Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter.

Researchers of the University of the Basque Country reveal some of the secrets of Saturn's mysterious hexagonal wave, including its rotation period, which could be that of the planet itself Caption: On the left, Saturn is shown in images obtained in 2013 with the PlanetCam and Astralux cameras on the 1.23 m and 2.2 m…

Investegate announcements from Placing and Subscription

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) – Investment analysts at Cantor Fitzgerald lowered their FY2023 earnings per share estimates for SELLAS Life Sciences Group in a research report issued to clients and investors on Monday, November 13th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($1.04) […]

The stock of SELLAS Life Sciences Group Inc (NASDAQ: SLS) has decreased by -2.70 when compared to last closing price of 0.91.Despite this, the company has seen a loss of -8.53% in its stock price over the last five trading days. GlobeNewsWire reported 2023-10-17 that NEW YORK, Oct. 17, 2023 (GLOBE N

– FDA feedback indicates Company’s CMC plans are in alignment with FDA’s requirements and expectations towards a BLA –

Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14...